Manager × security

Y.D. More Investments Ltd TEVAN holdings history

TEVA PHARMACEUTICAL-SP ADR · CUSIP 881624209 · CIK 1870364

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Y.D. More Investments Ltd reported 2.62M TEVAN (shares), valued at $88.74M, or 2.72% of its reported non-derivative portfolio. Filed 2026-08-05.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.72%
Shares
2.62M
2,619,250
Reported value
$88.74M
USD

Shares increased 61.90%; reported value increased 82.12%, and weight changed +0.85 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.72%2,619,250SEC filing ↗Filed Aug 5, 2026
Q1 20261.87%1,617,800SEC filing ↗Filed May 4, 2026
Q4 20252.37%1,615,900SEC filing ↗Filed Jan 21, 2026
Q3 20251.84%1,615,900SEC filing ↗Filed Nov 10, 2025
Q2 20251.08%932,750SEC filing ↗Filed Aug 11, 2025
Q1 20250.12%86,250SEC filing ↗Filed May 12, 2025
Q4 20240.19%98,700SEC filing ↗Filed Jan 27, 2025
Q3 20240.20%105,800SEC filing ↗Filed Nov 5, 2024
Q2 20240.17%105,500SEC filing ↗Filed Aug 8, 2024
Q1 20240.25%98,600SEC filing ↗Filed May 13, 2024
Q4 20230.15%75,420SEC filing ↗Filed Feb 6, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20230.15%75,420$787.38KThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 6, 2024
Q1 20240.25%98,600$1.39MShares increased 30.73%; reported value increased 76.69%, and weight changed +0.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2024
Q2 20240.17%105,500$1.71MShares increased 7.00%; reported value increased 23.23%, and weight changed -0.08 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 8, 2024
Q3 20240.20%105,800$1.91MShares increased 0.28%; reported value increased 11.21%, and weight changed +0.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 5, 2024
Q4 20240.19%98,700$2.18MShares decreased 6.71%; reported value increased 14.10%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jan 27, 2025
Q1 20250.12%86,250$1.33MShares decreased 12.61%; reported value decreased 39.06%, and weight changed -0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 12, 2025
Q2 20251.08%932,750$15.63MShares increased 981.45%; reported value increased 1079.25%, and weight changed +0.96 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 20251.84%1,615,900$32.64MShares increased 73.24%; reported value increased 108.80%, and weight changed +0.76 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 10, 2025
Q4 20252.37%1,615,900$50.43MShares unchanged; reported value increased 54.50%, and weight changed +0.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jan 21, 2026
Q1 20261.87%1,617,800$48.73MShares increased 0.12%; reported value decreased 3.38%, and weight changed -0.50 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 4, 2026
Q2 20262.72%2,619,250$88.74MShares increased 61.90%; reported value increased 82.12%, and weight changed +0.85 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 5, 2026
Y.D. More Investments Ltd · TEVA PHARMACEUTICAL-SP ADR

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1870364","quarter":"2026Q2","cusip":"881624209"}

get_institutional_manager_history
{"cik":"1870364","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.